Medicus Pharma Highlights Teverelix Phase I Data and $6 Billion Market Opportunity
Medicus Pharma will present Phase I data on Teverelix at AACE 2026, showing sustained estradiol suppression (Tmax 0.5–2 h, half-life 14–23 days) and bone biomarker stability in 48 premenopausal women. The company projects Teverelix as the first injectable GnRH antagonist in women’s health and advanced prostate cancer, targeting a $6 billion market.
1. Phase I Clinical Data
Medicus Pharma enrolled 48 premenopausal women across two Phase I studies (HFV1 and HFV2) evaluating single-dose subcutaneous Teverelix. Results demonstrated predictable, dose-dependent estradiol suppression within the 30–50 pg/mL therapeutic window, supporting potential efficacy in hormone-driven conditions.
2. Pharmacokinetics
Teverelix displayed rapid absorption (Tmax 0.5–2 hours) with a secondary exposure peak at 1–3 weeks and a terminal half-life of 14–23 days. These properties support infrequent dosing strategies and a depot formulation approach.
3. Bone Turnover and Safety
Bone turnover biomarkers DPD and NTx remained within normal ranges with changes ≤10% at Day 29, indicating minimal impact on bone health. No unexpected safety signals were observed, suggesting a favorable long-acting injectable profile.
4. Market Opportunity and Development Plans
The company positions Teverelix as the first long-acting injectable GnRH antagonist for women’s health (endometriosis, uterine fibroids) and advanced prostate cancer, targeting a combined $6 billion market. Precision‐guided Phase II patient studies are planned to optimize therapeutic response.